Objective To investigate the efficacy of crizotinib capsule combined with vinorelbine+cisplatin(NP)regi-men in the treatment of advanced non-small cell lung cancer.Method A total of 104 patients with advanced non-small cell lung cancer were divided into NP group(n=51)and crizotinib group(n=53).Patients in NP group were treated with NP regimen,and patients in crizotinib group were treated with crizotinib capsule on the basis of NP group.The efficacy,serum tumor markers,immune function indexes and the incidence of adverse reactions were compared between the two groups.Result The total effective rate of crizotinib group was significantly higher than that of NP group,the difference was statistically significant(P＜0.01).After treatment,the levels of carcinoembryonic antigen(CEA),neuronal specific enolase(NSE)and cyto-keratin 19 fragment antigen 21-1(CYFRA21-1)in both groups were lower than those before treatment,and the levels of NSE,CEA and CYFRA21-1 in crizotinib group were lower than those in NP group,the differ-ences were statistically significant(P＜0.05).After treatment,the levels of CD3+,CD4+in two groups were higher than those before treatment,the levels of CD8+in two groups were lower than those before treatment,and the levels of CD3+,CD4+and CD8+in crizotinib group were higher than those in NP group,the differences were statistically significant(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclu-sion Crizotinib capsule combined with NP regimen can improve the clinical efficacy of advanced non-small cell lung cancer patients,reduce the level of serum tumor markers,improve the immune function,and do not increase adverse reac-tions.
维普
万方数据